639

Kim K H[1], Kim G N[2], Lee K S[1]
1. *Dongguk University Medical Center,* ***2.*** *CHA Gumi Medical Center*

RISK FACTOR FOR SURGERY IN MEN WITH ACUTE URINARY RETENTION TREATED ALPHA BLOCKER

Hypothesis / aims of study
To assess the risk factor of surgery in 95 men with acute urinary retention (AUR) treated with alpha blocker in real life practice unable to void for yourself after removing of Foley catheter

Study design, materials and methods
A retrospective analysis was performed on 95 patients who had undergone surgery or medical treatment for acute urinary retention from July 2005 to September 2010. A total of 95 patients who underwent catheterization for AUR were retrospectively subdivided into medical treatment (group1, n=70) or surgery treatment (group2, n=25).
age, prostate specific antigen (PSA), International Prostate Symptom Score (IPSS), duration of catheter, residual urine volume, and prostate size by ultrasound were compared between the two groups. Men were excluded if they had cerebrovascular accident, disease associated with neurologic disorder.

Results
There were no statistical differences between the two groups with respect to the mean values of the age, PSA, residual urine volume, history of prior AUR, duration of catheterization and the degree of symptom score. There was a significant relationship between surgery for AUR and the prostate size (p=0.018). The prostate size was higher in the surgery group than the medical group (37.5 ± 1.3 vs. 31.5 ± 1.3g, respectively)(Table 1).

Interpretation of results
The association for surgery of AUR with the prostate size was stronger than that which existed with residual urine volume
Concluding message
The association for surgery of AUR with the prostate size was stronger than that which existed with residual urine volume. Thus prostate size is an important risk factor for surgery of AUR in patients with benign prostatic hyperplasia.

Table 1

	Group 1	Group 2	P value
Age (year)	68.7 ± 8.8	70.3 ± 5.3	0.392
PSA (ng/dl)	6.6 ± 4.0	6.1 ± 2.1	0.735
Prostate size (gm)	31.5 ± 1.3	37.5 ± 1.3	0.018
Residual urine (ml)	817.7 ± 294.4	904.2 ± 448.0	0.279
Duration of catheter (day)	4.9 ± 2.1	5.2 ± 1.7	0.927
IPSS	20.5 ± 9.3	24.1 ± 9.7	0.268

Specify source of funding or grant	**none**
Is this a clinical trial?	**Yes**
Is this study registered in a public clinical trials registry?	**No**
Is this a Randomised Controlled Trial (RCT)?	**No**
What were the subjects in the study?	**NONE**